Cancer cells resist chemotherapy because of their fibrotic interstitial (stromal) environment; fibrosis strangles cells, which then turn cancerous and resist chemo and radiation.

Original statement

حذّر الدكتور ضياء العوضي من العلاج الكيميائي والجراحة لإزالة الأورام، معتبراً أنها لا تعالج الأسباب الجذرية، وأن الجسم سيعيد تفعيل خطته الدفاعية في مكان آخر، ورأى أن الخلايا السرطانية تقاوم العلاج الكيماوي بسبب بيئتها الخلالية المتليفة.

not verbatim – paraphrase. Translation by the project; the Arabic wording is authoritative.

Translation

Cancer cells resist chemotherapy because of their fibrotic interstitial (stromal) environment; fibrosis strangles cells, which then turn cancerous and resist chemo and radiation.

Origin

Source status

Archive quote (no location given)

Attribution

Elawady (archive paraphrase; source video not given)

Origin

https://eltayebat.com/rule/chemo-radiation/

Attribution uncertainty

The archive attributes this text to Dr. Diaa in its 'د. ضياء يقول' box but gives no video reference. Transcript check (the project's research files, keyword search of 307 archive transcripts): found_close_paraphrase. The link between the interstitial (stromal) environment and chemotherapy resistance/aggressiveness is found in PI73-XbTbwU and the fibrosis image in o8BWuF9wmoM (both already alt sources); no single passage contains the whole quote.

Claimed mechanism

Fibrosis of interstitial tissue -> hypoxic cells -> cancer and resistance

Claimed health effect

Chemoresistance

Population concerned

Cancer patients

Geographic restriction by Elawady

none found

Diverging source versions

Scientific assessment

Mostly false – Essential parts of the statement are not supported by the evidence or are strongly exaggerated.

Certainty of evidence: low – Further research is likely to change the assessment considerably.

1. What was claimed?

Chemoresistance is caused by the fibrotic interstitial environment; fibrosis creates cancer.

2. What is demonstrably correct?

Dense tumour stroma can impair drug delivery: in a genetically engineered mouse model of pancreatic cancer, only 32% of tumour vessels were perfused; depleting the stroma raised intratumoral gemcitabine metabolites by 60% and transiently prolonged survival (11 to 25 days) before tumours resumed growth (I-CHM-11). This supports only that tumour stroma can hinder drug delivery in one tumour type in mice. Chronic inflammation/fibrosis is a recognised risk setting for some cancers (not reviewed in detail here).

3. What is wrong or exaggerated?

As a universal rule it is wrong: many cancers are highly chemosensitive and curable (childhood ALL 5-year survival 90.4%, I-CHM-05; testicular cancer 95% 10-year survival, A-CHM-14). Resistance has multiple causes (tumour genetics, drug efflux, etc.). The step from 'resistance exists' to 'do not treat' is not supported.

4. What remains unclear?

The share of chemoresistance attributable to stroma in human cancers. No source reviewed here tests the claim that fibrosis causes malignant transformation or radiation resistance.

5. Which studies support it?

Partial, mechanistic only: I-CHM-11 (stroma hinders drug delivery in mouse pancreatic cancer); I-CHM-119 (review: tumour microenvironment can protect cancer cells from initial therapy); I-CHM-129 (stroma-rich ovarian tumours more often platinum-resistant in one of two cohorts; no association in the other).

6. Which studies contradict it?

I-CHM-118 (phase III RCT: degrading tumour stroma added to chemotherapy did not improve survival, HR 1.00); I-CHM-120 (in pancreatic cancer, a very stroma-rich tumour, adjuvant chemotherapy doubled 5-year survival); I-CHM-117 (in mice, removing stroma made tumours more aggressive); I-CHM-05, A-CHM-14 (highly chemosensitive curable cancers).

7. What applies to Germany and Europe?

Not region-specific: tumour biology and chemosensitivity do not depend on the country; no Europe-specific data were reviewed.

8. What is known about Egypt?

Not region-specific; no Egyptian data were reviewed. Differences in access to treatment do not change the biology.

9. What practical conclusion is appropriate?

Resistance to one drug is a reason to choose other treatments with the oncologist, not to stop treatment.

Assessment details

Rationale for certainty of evidence

Mechanistic animal data support a partial stromal contribution in some tumours; as a general explanation it conflicts with the high chemosensitivity of many cancers. Evidence base reviewed here is limited.

Source quality

Archive paraphrase + transcripts.

Regional scope of the claim

general (biological/medical)

Last reviewed

26 October 2026 provisional

Scientific evidence in detail

Overinterpreted – A real finding exists, but the claim draws more from it than the data allow (e.g. association taken as cause, animal data applied to humans, small effect presented as large).

Research question: Is fibrotic tumour stroma a general cause of cancer and of resistance to chemotherapy and radiotherapy, such that treatment is futile?

Study results as reported by the authors. Our assessment follows below.

Open questions

Role of fibrosis in specific organ cancers (liver, lung) not reviewed in detail.

How deeply was this checked?

8 linked studies: 2 checked in full text (2 of them with a structured risk-of-bias assessment), 6 on the basis of the abstract, 0 bibliographically only. No formal assessment with two independent reviewers and no independent human expert review has taken place yet.

Last scientific review: 26 October 2026

In plain language

Some tumours, like pancreatic cancer, are surrounded by dense tissue that can keep drugs out. This is one of several reasons why some cancers respond poorly. But many cancers, such as childhood leukaemia and testicular cancer, respond very well to chemotherapy and are usually cured.

Studies on this claim

Regional context

Germany / EU

Not region-specific: tumour biology and chemosensitivity do not depend on the country; no Europe-specific data were reviewed.

Egypt

Not region-specific; no Egyptian data were reviewed. Differences in access to treatment do not change the biology.

What applies in my country?

General scientific assessment

Mostly false Stroma can contribute to drug resistance in some tumours, but it is not a general explanation and does not justify avoiding treatment.

This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.

References

1. Environment-mediated drug resistance: a major contributor to minimal residual disease.. Meads MB et al.. Nat Rev Cancer 2009 · PMID 19693095 · DOI 10.1038/nrc2714
2. Tumor-Stroma Proportion to Predict Chemoresistance in Patients With Ovarian Cancer.. Lou E et al.. JAMA Netw Open 2024 · PMID 38411963 · DOI 10.1001/jamanetworkopen.2024.0407
3. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group.. Hunger SP et al.. J Clin Oncol 2012 · PMID 22412151 · DOI 10.1200/JCO.2011.37.8018
4. Toxicities Associated with Cisplatin-Based Chemotherapy and Radiotherapy in Long-Term Testicular Cancer Survivors.. Fung C et al.. Adv Urol 2018 · PMID 29670654 · DOI 10.1155/2018/8671832
5. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma.. Rhim AD et al.. Cancer Cell 2014 · PMID 24856585 · DOI 10.1016/j.ccr.2014.04.021
6. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma.. Van Cutsem E et al.. J Clin Oncol 2020 · PMID 32706635 · DOI 10.1200/JCO.20.00590
7. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.. Oettle H et al.. JAMA 2013 · PMID 24104372 · DOI 10.1001/jama.2013.279201
8. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer.. Olive KP et al.. Science 2009 · PMID 19460966 · DOI 10.1126/science.1171362